gp 130-mediated pathway and heart failure

Future Cardiology

Volumn 4, Issue 4, 2008, Pages 427-437

  Yamauchi Takihara, Keiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Cardiac remodeling; Cytokine; Heart failure; Hypertrophy; Signal trasnduction

Indexed keywords

GLYCOPROTEIN GP 130; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SCAVENGER; STAT PROTEIN; STAT3 PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CELL ENERGY; CELL SURVIVAL; GENE TARGETING; HEART DEVELOPMENT; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; LIGAND BINDING; MECHANICAL STRESS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS MYOCARDITIS;

EID: 47149119197     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.4.4.427     Document Type: Review

References (79)

1. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S: Circulating interleukin-6 in severe heart failure. Am. J. Cardiol. 79, 1128-1131 (1997).
2. Torre-Amione G, Bozkurt B, Deswal A, Mann DL: An overview of tumor necrosis factor α and the failing human heart. Curr. Opin. Cardiol. 14, 206-210 (1999).
3. Kishimoto T, Akira S, Narazaki M, Taga T: Interleukin-6 family of cytokines and gp 130. Blood, 86, 1243-1254 (1995).
4. Hirano T, Nakajima K, Hibi M: Signaling mechanisms through gp 130: a model of the cytokine system. Cytokine Growth Factor Rev. 8, 241-252 (1997).
5. Chien KR: Stress pathways and heart failure. Cell 98, 555-558 (1999).
6. Yamauchi-Takihara K: gp 130-mediated pathway and left ventricular remodeling. J. Card. Fail. 8(Suppl. 7), S374-S378 (2002).
7. Yamauchi-Takihara K, Kishimoto T: A novel role for STAT3 in cardiac remodeling. Trends Cardiovasc. Med. 10(7), 298-303 (2000).
8. Hirota H, Chen J, Betz UA et al.: Loss of a gp 130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97, 189-198 (1999).
9. Kunisada K, Hirota H, Fujio Y et al.: Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp 130 in cardiac myocytes. Circulation 94(10), 2626-2632 (1996).
10. Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, Kishimoto T: Activation of gp 130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98(4), 346-352 (1998).
11. Uozumi H, Hiroi Y, Zou Y et al.: gp 130 plays a critical role in pressure overload-induced cardiac hypertrophy. J. Biol. Chem. 276, 23115-23119 (2001).
12. Pan J, Fukuda K, Kodama H et al.: Involvement of gp 130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart. Heart Vessels 13, 199-208 (1998).
13. Takahashi N, Saito Y, Kuwahara K et al.: Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. J. Mol. Cell Cardiol. 38(1), 185-192 (2005).
14. Nakaoka Y, Nishida K, Fujio Y et al.: Activation of gp 130 transduces hypertrophic signal through interaction of scaffolding/ docking protein Gab 1 with tyrosine phosphatase SHP2 in cardiomyocytes. Circ. Res. 93(3), 221-229 (2003).
15. Lopez N, Diez J, Fortuno MA: Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J. Mol. Cell Cardiol. 41(5), 902-913 (2006).
16. Tone E, Kunisada K, Kumanogoh A et al.: gp 130-dependent signalling pathway is not enhanced in gp 130 transgenic heart after LIF stimulation. Cytokine 12(10), 1512-1518 (2000).
17. Inagaki-Ohara K, Hanada T, Yoshimura A: Negative regulation of cytokine signaling and inflammatory diseases. Curr. Opin. Pharmacol. 3(4), 435-442 (2003).
18. Fujio Y, Kunisada K, Hirota H, Yamauchi-Takihara K, Kishimoto T: Signals through gp 130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J. Clin. Invest. 99, 2898-2905 (1997).
19. Oh H, Fujio Y, Kunisada K et al.: Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J. Biol. Chem. 273(16), 9703-9710 (1998).
20. Negoro S, Oh H, Tone E et al.: Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 103, 555-561 (2001).
21. Negoro S, Kunisada K. Tone E et al.: Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc. Res. 47, 797-805 (2000).
22. Hishinuma S, Funamoto M, Fujio Y, Kunisada K. Yamauchi-Takihara K: Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochem. Biophys. Res. Commun. 264, 436-440 (1999).
23. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL: Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J. Clin Invest. 94, 1621-1628 (1994).
24. Itoh G, Tamura J, Suzuki M et al.: DNA fragmentation of human infarcted myocardial cells demonstrated by the nick end labeling method and DNA agarose gel electrophoresis. Am. J. Pathol. 146, 1325-1331 (1995).
25. Kajstura J, Cheng W, Reiss K et al.: Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab. Invest. 74, 86-107 (1996).
26. Tanaka M, Ito H, Adachi S et al.: Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ. Res. 75, 426-433 (1994).
27. Teiger E, Than VD, Richard L et al.: Apoptosis in pressure overload-induced heart hypertrophy in the rat. J. Clin. Invest. 97, 2891-2897 (1996).
28. Zou Y, Takano H, Mizukami M et al.: Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. Circulation 108(6), 748-753 (2003).
29. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R: An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc. Natl Acad Sci. USA 98, 9050-9055 (2001).
30. Aikawa R, Komuro I, Yamazaki T et al.: Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J. Clin. Invest. 100, 1813-1821 (1997).
31. Wang X, McCullough KD, Franke TF, Holbrook NJ: Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J. Biol. Chem. 275, 14624-14631 (2000).
32. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC: Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197, 165-167 (1977).
33. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction ('stunned myocardium). J. Am Coll. Cardiol. 12, 239-249 (1988).
34. Singh N, Dhalla AK, Seneviratne C, Singal PK: Oxidative stress and heart failure. Mol. Cell Biochem. 147, 77-81 (1995).
35. Negoro S, Kunisada K. Fujio Y et al.: Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase, Circulation 104, 979-981 (2001).
36. Tsan MF, White JE, Treanor C, Shaffer JB: Molecular basis for tumor necrosis factor-induced increase in pulmonary superoxide dismutase activities. Am. J. Physiol. 259, L506-L512 (1990).
37. Dougall WC, Nick HS: Manganese superoxide dismutase: a hepatic acute phase protein regulated by interleukin-6 and glucocorticoids. Endocrinology 129, 2376-2384 (1991).
38. Oshima Y, Fujio Y, Nakanishi T et al.: STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc. Res. 65(2), 428-435 (2005).
39. Hilfiker-Kleiner D, Hilfiker A, Fuchs M et al.: Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ. Res. 95(2), 187-195 (2004).
40. Karakurum M, Shreeniwas R, Chen J et al.: Hypoxic induction of interleukin-8 gene expression in human endothelial cells. J. Clin. Invest. 93, 1564-1570 (1994).
41. Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T: Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 91, 1520-1524 (1995).
42. Yan SF, Tritto I, Pinsky D et al.: Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J. Biol. Chem. 270, 11463-11471 (1995).
43. Ladoux A, Frelin C: Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem. Biophys. Res. Commun. 195, 1005-1010 (1993).
44. Funamoto M, Fujio Y, Kunisada K et al.: Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J. Biol. Chem. 275, 10561-10566 (2000).
45. Osugi T, Oshima Y, Fujio Y et al.: Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J. Biol. Chem. 277(8), 6676-6681 (2002).
46. Kamimura D, Ishihara K, Hirano T: IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149, 1-38 (2003).
47. Kunisada K, Negoro S, Tone E et al.: Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl Acad. Sci. USA 97(1), 315-319 (2000).
48. Harada M, Qin Y, Takano H et al.: G-CSF prevents cardiac remodeling after myocardial infarction by activating the JAK-STAT pathway in cardiomyocytes. Nat. Med. 11(3), 305-311 (2005).
49. Jacoby JJ, Kalinowski A, Liu MG et al.: Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc. Natl Acad. Sci. USA 100(22), 12929-12934 (2003).
50. Takano H, Qin Y, Hasegawa H et al.: Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction. J. Mol. Med. 84(3), 185-193 (2006).
51. Calabrese F, Thiene G: Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc. Res. 60(1), 11-25 (2003).
52. Huber SA, Gauntt CJ, Sakkinen P: Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Adv. Virus Res. 51, 35-80 (1999).
53. Bowles NE, Towbin JA. Molecular aspects of myocarditis. Curr. Opin. Cardiol. 13(3), 179-184 (1998).
54. Bowles NE, Bowles KR, Towbin JA: Viral genomic detection and outcome in myocarditis. Heart Fail. Clin. 1(3), 407-417 (2005).
55. Suddaby EC: Viral myocarditis in children. Crit. Care Nurse 16(4), 73-82 (1996).
56. Okuno M, Nakagawa M, Shimada M, Saito M, Hishinuma S, Yamauchi-Takihara K: Expressional patterns of cytokines in a murine model of acute myocarditis: early expression of cardiotrophin-1. Lab. Invest. 80(3), 433-440 (2000).
57. Yasukawa H, Yajima T, Duplain H et al.: The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Invest. 111(4), 469-478 (2003).
58. Yajima T, Yasukawa H, Jeon ES et al.: Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation 114(22), 2364-2373 (2006).
59. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. 72(6), 561-566 (1994).
60. Aukrust P, Ueland T, Lien E et al.: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 83(3), 376-382 (1999).
61. Tsutamoto T, Hisanaga T, Wada A et al.: Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is in important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol. 31(2), 391-398 (1998).
62. Maeda K, Tsutamoto T, Wida A et al.: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J. Am. Coll. Cardiol. 36(5), 1587-1593 (2000).
63. Talwar S, Downie PF, Squire IB, Barnett DB, Davies JD, Ng LL: An immunoluminometric assay for cardiotrophin-1: a newly identified cytokine is present in normal human plasma and is increased in heart failure. Biochem. Biophys. Res. Commun. 261(3), 567-571 (1999).
64. Tsutamoto T, Wada A, Maeda K et al.: Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 38(5), 1485-1490 (2001).
65. Jougasaki M, Tachibana I, Luchner A, Leskinen H, Redfield MM, Burnett JC Jr: Augmented cardiac cardiotrophin-1 in experimental congestive hear, failure. Circulation 101(1), 14-17 (2000).
66. Wang F, Seta Y, Baumgarten G, Engel DJ, Sivasubramanian N, Mann DL: Functional significance of hemodynamic overload-induced expression of leukemia-inhibitory factor in the adult mammalian heart. Circulation 103(9), 1296-1302 (2001).
67. Eiken HG, Oie E, Damas JK et al.: Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur. J. Clin. Invest. 31(5), 389-397 (2001).
68. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T: Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 106(12), 1442-1446 (2002).
69. Gonzalez A, Ravassa S, Loperena I et al.: Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J. Hypertens. 25(10), 2148-2157 (2007).
70. Hirota H, Izumi M, Hamaguchi T et al.: Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels 19(5), 237-241 (2004).
71. Gwechenberger M, Pacher R, Berger R et al.: Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression. J. Heart Lung Transplant 24(12), 2190-2195 (2005).
72. Narazaki M, Yasukawa K, Saito T et al.: Soluble form of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82(4), 1120-1126 (1993).
73. Matsui H, Fujio Y, Kunisada K, Hirota H, Yamauchi-Takihara K: Leukemia inhibitory factor induces a hypertrophic response mediated by gp130 in routine cardiac myocytes. Res. Commun. Mol. Pathol. Pharmacol. 93(2), 149-162 (1996).
74. Pennica D, Wood WI, Chien KR: Cardiotrophin-1: a multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Cytokine Growth Factor Rev. 7(1), 81-91 (1996).
75. Hilfiker-Kleiner D, Kaminski K, Podewski E et al.: A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128(3), 589-600 (2007).
76. Boengler K, Buechert A, Heinen Y et al.: Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ. Res. 102(1), 131-135 (2008).
77. Podewski EK, Hilfiker-Kleiner D, Hilfiker A et al.: Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 107(6), 798-802 (2003).
78. Mann DL, McMurray JJ, Packer M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109(13), 1594-1602 (2004).
79. Mann DL: Targeted anticytokine therapy and the failing heart. Am. J. Cardiol. 95(11A), 9C-16C; discussion 38C-40C (2005).